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Post-marketing surveillanceA B S T R A C T
Aims: This study investigated the hypoglycemia risk in people with type 2 diabetes (T2D)
who initiated or switched to insulin glargine 300 U/mL (Gla-300) by stratifying them by
age and renal function.
Methods: We examined data from 4621 people with T2D (1227 insulin-naı̈ve and 3394
insulin-experienced) of the X-STAR study, a prospective, observational, 12-month study
conducted from December 2015 to August 2018 in Japan. Participants were stratified by
age (<65, 65 to <75, and 75 years) and estimated glomerular filtration rate (eGFR) (90,
60 to <90, 30 to <60, and <30 mL/min/1.73 m2). Hypoglycemia was defined according to
the Ministry of Health, Labour and Welfare manual of Japan.
Results: No apparent increase in the proportion of people who experienced hypoglycemia
was found in all subgroups. The proportions were 2.9–3.5% and 2.7–5.2% of insulin-naı̈ve
and insulin-experienced people, respectively, for age subgroups, and 2.4–4.7% and 4.6–
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 74.8%, respectively, for eGFR subgroups. The result was similar for HbA1c levels below and at
or above 7.0% in all age subgroups.
Conclusions: Our study found no apparent increase in the hypoglycemia risk in people with
older age and renal impairment who were administered Gla-300. These results would pro-
vide reassuring information on Gla-300 use.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Insulin therapy is an established option to improve glycemic
control in people with type 2 diabetes (T2D) and, in reality,
tends to be reserved for those with advanced stage of dia-
betes. Insulin is highly efficacious in terms of lowering glu-
cose; however, it imposes potential hypoglycemic risk [1].
Furthermore, hypoglycemia has a variety of negative impacts
on people with diabetes (e.g., decline in cognitive function [2],
arrhythmia [3,4], or cardiovascular events [5]) and eventually
could lead to death [6].
Age is a well-known risk factor of hypoglycemia [7–9].
Specifically, age-related factors, such as difficulty in appropri-
ate self-management (blood glucose monitoring, subcuta-
neous injection, and glucose intake for hypoglycemia) and
diminished drug metabolism, are likely to increase the risk
of hypoglycemia upon insulin treatment. Furthermore,
blunted counterregulatory activation in response to hypo-
glycemia is often present in the elderly, which could also
increase the risk of asymptomatic hypoglycemia and subse-
quent severe hypoglycemia [9,10]. Chronic kidney disease
(CKD) is another risk factor of hypoglycemia, probably due
to the decreased renal clearance of glucose-lowering drugs
[11]. CKD is frequently associated with T2D. In Japan, 25.2%
(775/3071) of people with T2D had CKD (eGFR < 60 mL/
min/1.73 m2) [12]. Thus, investigation on how age and renal
function affect hypoglycemic events upon insulin treatment
in the real-world clinical setting would provide essential
information.
Insulin glargine 300 U/mL (Gla-300 [Toujeo in the United
States and Europe; Lantus XR in Japan]), available since
2015, is a second-generation basal insulin that is character-
ized by more stable and prolonged pharmacokinetic and
pharmacodynamic profiles compared to glargine 100 U/mL
(Gla-100), thereby contributing to sustained glycemic control
with a minimized risk of hypoglycemia [13–18]. Such benefi-
cial effects of Gla-300 were also demonstrated in people aged
65 years with T2D [19–21]. The X-STAR study, a post-
marketing study of Gla-300 in people with diabetes, was con-
ducted in Japan with a maximum of 1-year follow-up [22].
Overall, the results suggest that Gla-300 is an effective treat-
ment option with no new safety concerns. However, to date,
whether Gla-300 can be safely used by people with a high-
risk of hypoglycemia such as those with older age or renal
impairment is yet to be explored in clinical settings in Japan.
The objective of this subgroup analysis was to investigate
how the proportion of people with hypoglycemia who initi-
ated or switched to Gla-300 varies with its known risk factors




Details of the X-STAR study are available elsewhere [22]. In
brief, the X-STAR study was a prospective, observational, 12-
month study conducted from December 2015 to August 2018
in accordance with the pharmaceutical affairs law and the
ministerial ordinance of Good Post-Marketing Study Practice
in Japan. Ethical committee approval and written informed
consent were waived for this study. People with diabetes to
whom Gla-300 was newly prescribed were enrolled at the par-
ticipating medical institutions under a contract with Sanofi K.
K. (Tokyo, Japan) and were followed up for 12 months. The
participants were centrally enrolled within 14 days from the
day that Gla-300 was first administered, and their anon-
ymized data were entered into an electronic data capturing
system. The treating physicians managed doses of Gla-300
as they would in their routine practice in accordance with
the Japanese package insert of Gla-300 [23]. Hypoglycemia
was diagnosed by treating physicians according to reports
from the participants when they had symptoms (dizziness,
weakness, etc.), signs of sympathetic response (tachycardia,
sweating, etc.) or by central nervous system dysfunction
(coma, seizure, etc.), and glucose levels (<70 mg/dL) [24].
2.2. Study population
This study examined data from 4621 people with T2D (1227
insulin-naı̈ve and 3394 insulin-experienced) enrolled in the
X-STAR study. Among the enrolled, people who had never
received insulin prior to the Gla-300 initiation at baseline
were categorized as ‘‘insulin-naı̈ve,” and those who had been
treated with other insulin products prior to Gla-300 adminis-
tration at baseline were categorized as ‘‘insulin-experienced,”
for which Gla-300 either replaced previously used insulin
products or was administered in combination. Details of the
study enrollment (e.g., participating institutions, inclusion
and exclusion criteria) are described in Odawara et al. [22].
To explore the hypoglycemia risk in subgroups during the
Gla-300 administration for 12 months, both insulin-naı̈ve and
insulin-experienced people were stratified according to age
(<65, 65–<75, and 75 years), estimated glomerular filtration
rate (eGFR: <30, 30–<60, 60–<90, and 90 mL/min/1.73 m2),
and history of hypoglycemia within 3 months before Gla-300
administration.
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Baseline demographics and clinical characteristics examined
in this study included age, sex, duration of diabetes, body
weight, height, body mass index (BMI), comorbidities, hospi-
talization, types of insulins, and oral antidiabetic drugs. We
assessed the Gla-300 daily dose monitored at baseline, month
6 (days 169–196), and month 12 (days 337–364). We also
assessed HbA1c levels (National Glycohemoglobin Standard-
ization Program), fasting plasma glucose (FPG, including labo-
ratory measurement or self-monitored plasma glucose), and
body weight measured at baseline (the latest data within
8 weeks prior to Gla-300 initiation), month 6 (±6 weeks) and
month 12 (±6 weeks).
2.4. Statistical analysis
All data were expressed as mean ± standard deviation (SD) for
continuous variables, or as number and proportion of people
in each category for categorical data. Baseline characteristics
of insulin-naı̈ve and insulin-experienced people were strati-
fied by subgroups of age and eGFR. The mean Gla-300 admin-
istration, HbA1c level, body weight, and FPG level were
calculated at baseline and 12 months after separately for
the age and eGFR subgroups, and changes between these time
points were also calculated. For comparison of Gla-300 dose,
HbA1c level, body weight, and FPG level data at month 12 (last
observation carried forward [LOCF]) with those at baseline,
the paired t-test was used. Analogous descriptive analysis
as above was also performed for people who did or did not
experience hypoglycemia during the study period.
Proportions of insulin-naı̈ve and insulin-experienced peo-
ple who experienced 1 hypoglycemia during the 12-month
follow-up was calculated separately for the age and eGFR sub-
groups. The proportions by age were further stratified accord-
ing to HbA1c level at month 12 (<6.5%, 6.5%–<7.0%, 7.0%–
<7.5%, 7.5%–<8.0%, and 8.0%). The LOCF approach was used
for imputing the missing value and described as month 12
(LOCF). All analyses were performed using the SAS software
release 9.4 (SAS Institute, Inc., Cary, NC, USA). The signifi-
cance level was defined as a two-sided p-value < 0.05.3. Results
3.1. Study population
The baseline characteristics of 4621 people with T2D (1227
insulin-naı̈ve and 3394 insulin-experienced) are summarized
by age in Table 1 and by eGFR in Table 2. Of those aged <65,
65–<75, and 75 years, males represented 71.5%, 62.4%, and
55.9% in the insulin-naı̈ve group and 63.0%, 59.8%, and
52.1% in insulin-experienced group, respectively. Mean ± SD
BMI was 26.0 ± 5.0 kg/m2, 23.8 ± 3.8 kg/m2, and 23.0 ± 3.8 kg/
m2 in insulin-naı̈ve and 26.9 ± 5.3, 24.7 ± 3.9, and 24.0 ± 3.8 in
insulin-experienced people, respectively. There was no appar-
ent trend in terms of sex and BMI among eGFR subgroups in
both insulin-naı̈ve and insulin-experienced groups, but the
proportion of males were 69.3%, 67.5%, 69.4%, and 48.8% in
eGFR < 30, 30 to <60, 60 to <90, and 90 mL/min/1.73 m2,respectively in the insulin-naı̈ve group (Table 2). In insulin-
naı̈ve people, baseline HbA1c levels were the highest in the
subgroup aged <65 years (mean ± SD, 10.4 ± 2.3%) and with
eGFR > 90 mL/min/1.73 m2 (10.7 ± 2.3%). Also, in insulin-
experienced group, these two subgroups showed slightly
higher baseline HbA1c levels than other subgroups.
In both insulin-naı̈ve and insulin-experienced people,
dipeptidyl peptidase-4 (DPP-4) inhibitors were the commonly
used oral antidiabetic drugs (OADs) with 60.2% and 44.6%
among overall people, respectively. Particularly, DPP-4 inhibi-
tors were more commonly prescribed to people with older age
and lower eGFR. Biguanides and sulfonylureas were used by
40.8% and 42.5% in overall insulin-naı̈ve people and by
31.3% and 13.8% in overall insulin-experienced people.
Sodium-glucose transport protein 2 (SGLT2) inhibitors were
used less commonly, with 16.4% and 15.6% of overall
insulin-naı̈ve and insulin-experienced people, respectively.
Unlike DPP-4 inhibitors, the proportion of people taking
SGLT2 inhibitors were lower in older and lower eGFR sub-
groups in both insulin-naı̈ve and insulin-experienced groups
(Tables 1 and 2). The baseline characteristics in subgroups
of people with respect to hypoglycemia history before Gla-
300 administration are provided in Supplementary Table 1.
3.2. Gla-300 dose, HbA1c level, body weight, and FPG
level
The mean Gla-300 dose, HbA1c level, body weight, and FPG
level are summarized in Table 3 by age and in Table 4 by eGFR.
Changes ± SD in HbA1c levels from baseline to month 12
(LOCF) were 2.4 ± 2.5%, 1.6 ± 1.9%, and 1.4 ± 1.9% in
insulin-naı̈ve people aged <65, 65–<75, and 75 years, respec-
tively, and those in insulin-experienced people were 0.3 ± 1.
4%, 0.1 ± 1.0%, and 0.1 ± 1.0%, respectively (Table 3). With
respect to the eGFR category, changes in HbA1c level from
baseline to month 12 (LOCF) were 2.9 ± 2.6%, 2.0 ± 2.2%,
1.6 ± 2.1%, and 1.1 ± 1.7% in insulin-naı̈ve people of eGFR
90, 60–<90, 30–<60, and <30 mL/min/1.73 m2, respectively,
and 0.3 ± 1.4%, 0.2 ± 1.2%, 0.2 ± 1.2%, and 0.2 ± 1.1%,
respectively, in insulin-experienced people (Table 4). Results
stratified by history of hypoglycemia before Gla-300 adminis-
tration are provided in Supplementary Table 2.
Regarding HbA1c distribution at month 12 (LOCF) by age,
28.5%, 32.6%, and 22.3% of people aged <65, 65–<75, and
75 years old, respectively in the insulin-naı̈ve group were
below the HbA1c level of 7.0% (Fig. 1A), which is a target for
the prevention of micro- and macrovascular complications
[25]. In the insulin-experienced group, 23.1%, 24.2%, and
27.8% of people, respectively were below the HbA1c level of
<7.0%.
3.3. Hypoglycemia by age or eGFR
The proportion of people who experienced 1 hypoglycemia
during 12 months of Gla-300 administration had no general
patterns across the age and eGFR subgroups (Fig. 1B). Hypo-
glycemia was found in 2.9%, 2.6%, and 3.5% of insulin-naı̈ve
people aged <65, 65–<75, and 75 years old, respectively,
and 3.4%, 5.2%, and 2.7% of insulin-experienced people,
respectively. With respect to eGFR, 2.4%, 3.4%, 4.1%, and



















Age, years, mean ± SD 62.1 ± 14.1 50.7 ± 9.4 69.2 ± 3.0 80.1 ± 4.5 64.9 ± 12.5 53.3 ± 8.9 69.1 ± 2.9 80.0 ± 4.1
Male, n (%) 805 (65.6) 443 (71.5) 219 (62.4) 143 (55.9) 2015 (59.4) 913 (63.0) 695 (59.8) 407 (52.1)
Duration of diabetes, n 827 – 440 – 230 – 157 – 2550 – 1107 – 894 – 549 –
Mean ± SD, years 11.3 ± 8.8 7.9 ± 6.8 14.7 ± 9.1 15.6 ± 9.6 16.3 ± 9.4 13.2 ± 7.8 17.7 ± 9.2 20.4 ± 10.7
Hospitalization, n (%) 174 (14.2) 61 (9.8) 55 (15.7) 58 (22.7) 121 (3.6) 43 (3.0) 33 (2.8) 45 (5.8)
Body weight, n 1022 – 527 – 287 – 208 – 2914 – 1267 – 1001 – 646 –
Mean ± SD, kg 66.0 ± 15.6 72.0 ± 16.3 62.0 ± 12.1 56.6 ± 11.0 66.9 ± 15.2 73.4 ± 16.7 63.8 ± 11.8 58.8 ± 10.7
BMI†, n 1022 – 527 – 287 – 208 – 2910 – 1266 – 999 – 645 –
Mean ± SD, kg/m2 24.8 ± 4.7 26.0 ± 5.0 23.8 ± 3.8 23.0 ± 3.8 25.5 ± 4.7 26.9 ± 5.3 24.7 ± 3.9 24.0 ± 3.8
Comorbidity
Retinopathy 274 (22.3) 125 (20.2) 90 (25.6) 59 (23.0) 1242 (36.6) 509 (35.1) 457 (39.3) 276 (35.3)
Nephropathy 387 (31.5) 171 (27.6) 123 (35.0) 93 (36.3) 1445 (42.6) 544 (37.5) 532 (45.7) 369 (47.2)
Neuropathy 342 (27.9) 149 (24.0) 111 (31.6) 82 (32.0) 1208 (35.6) 467 (32.2) 444 (38.2) 297 (38.0)
Cardiovascular/ cerebrovascular diseases 203 (16.5) 50 (8.1) 79 (22.5) 74 (28.9) 713 (21.0) 192 (13.2) 283 (24.3) 238 (30.5)
HbA1c, n 1124 – 571 – 318 – 235 – 3217 – 1380 – 1103 – 734 –
Mean ± SD, % 9.8 ± 2.2 10.4 ± 2.3 9.2 ± 1.9 9.3 ± 2.0 8.0 ± 1.5 8.3 ± 1.7 7.8 ± 1.2 7.8 ± 1.3
FPG, n (%) 441 – 223 – 132 – 86 – 1037 – 448 – 361 – 228 –
Mean ± SD, mg/dl 232.0 ± 95.4 237.8 ± 95.3 210.4 ± 84.5 250.1 ± 105.9 156.3 ± 68.2 161.0 ± 75.7 149.9 ± 56.3 157.2 ± 69.4
eGFR, n (%) 905 – 455 – 255 – 195 – 2437 – 1002 – 854 – 581 –
Mean ± SD, mL/min/1.73 m2 77.4 ± 29.5 88.8 ± 29.8 69.1 ± 23.8 61.9 ± 24.6 67.6 ± 26.8 77.4 ± 29.7 64.3 ± 22.1 55.8 ± 21.6
<60 mL/min/1.73 m2, n (%) 236 (26.1) 60 (13.2) 80 (31.4) 96 (49.2) 934 (38.3) 243 (24.3) 347 (40.6) 344 (59.2)
GLP-1 receptor agonist†† 120 (14.4) 60 (16.5) 41 (15.4) 19 (9.4) 341 (10.0) 184 (12.7) 91 (7.8) 66 (8.5)
Insulin††, n (%)
Long-acting 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3110 (91.6) 1334 (92.0) 1074 (92.3) 702 (89.9)
Intermediate 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 20 (0.6) 8 (0.6) 7 (0.6) 5 (0.6)
Premix 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 150 (4.4) 51 (3.5) 44 (3.8) 55 (7.0)
Regular 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 24 (0.7) 10 (0.7) 9 (0.8) 5 (0.6)
Rapid 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1422 (41.9) 630 (43.4) 499 (42.9) 293 (37.5)
Oral antidiabetic drugs††, n (%)
Sulfonylurea 353 (42.5) 135 (37.2) 129 (48.5) 89 (44.1) 470 (13.8) 190 (13.1) 175 (15.0) 105 (13.4)
Biguanide 339 (40.8) 170 (46.8) 114 (42.9) 55 (27.2) 1061 (31.3) 580 (40.0) 362 (31.1) 119 (15.2)
DPP-4 inhibitor 500 (60.2) 195 (53.7) 160 (60.2) 145 (71.8) 1514 (44.6) 576 (39.7) 552 (47.5) 386 (49.4)
SGLT2 inhibitor 136 (16.4) 83 (22.9) 40 (15.0) 13 (6.4) 530 (15.6) 337 (23.2) 142 (12.2) 51 (6.5)
T2D, type 2 diabetes mellitus; SD, standard deviation; BMI, body mass index; FPG, fasting plasma glucose; eGFR, estimated glomerular filtration rate; GLP, glucagon-like peptide; DPP-4, dipeptidyl
peptidase-4; SGLT2, Sodium-glucose transport protein 2
† BMI is calculated as weight in kilograms divided by the square of the height in meters















































Table 2 – Baseline characteristics of insulin-naı̈ve and insulin-experienced people with T2D in the eGFR subgroups.
Insulin-naı̈ve Insulin-experienced

















Age, years, mean ± SD 53.3 ± 13.7 64 ± 12.2 70.3 ± 11.6 68.4 ± 11.9 55.8 ± 13.8 64.9 ± 10.8 70.3 ± 10.7 67.8 ± 13.1
Male, n (%) 199 (69.3) 258 (67.5) 134 (69.4) 21 (48.8) 229 (53.5) 663 (61.7) 425 (56.9) 117 (62.6)
Duration of diabetes, n 206 – 265 – 138 – 25 – 339 – 827 – 596 – 139 –
Mean ± SD, years 7.4 ± 7.5 11.5 ± 9.1 15 ± 9.7 14.1 ± 8.2 12.6 ± 7.6 16.5 ± 9.7 17.8 ± 9.8 19.9 ± 9.5
Hospitalization, n (%) 35 (12.2) 56 (14.7) 44 (22.8) 11 (25.6) 19 (4.4) 32 (3.0) 49 (6.6) 11 (5.9)
Body weight, n 257 – 342 – 172 – 36 – 378 – 964 – 651 – 155 –
Mean ± SD, kg 68.9 ± 18.0 65.6 ± 15.2 64.2 ± 12.5 63.1 ± 18.9 69.2 ± 19.1 66.4 ± 14.4 65.8 ± 13.9 68.1 ± 15.6
BMI†, n 257 – 342 – 172 – 36 – 377 – 964 – 649 – 155 –
Mean ± SD, kg/m2 25.3 ± 5.4 24.7 ± 4.8 24.6 ± 3.6 24.5 ± 5.2 26.1 ± 6.4 25.2 ± 4.4 25.6 ± 4.3 26.0 ± 5.0
Comorbidity
Retinopathy 52 (18.1) 89 (23.3) 59 (30.6) 22 (51.2) 119 (27.8) 365 (34.0) 350 (46.9) 114 (61.0)
Nephropathy 69 (24.0) 115 (30.1) 95 (49.2) 35 (81.4) 130 (30.4) 438 (40.7) 434 (58.1) 169 (90.4)
Neuropathy 66 (23.0) 114 (29.8) 70 (36.3) 25 (58.1) 133 (31.1) 371 (34.5) 351 (47.0) 102 (54.5)
Cardiovascular/ cerebrovascular diseases 252 (87.8) 320 (83.8) 150 (77.7) 29 (67.4) 378 (88.3) 880 (81.9) 524 (70.1) 118 (63.1)
HbA1c, n 284 – 377 – 191 – 34 – 425 – 1069 – 736 – 165 –
Mean ± SD, % 10.7 ± 2.3 9.7 ± 2.1 9.4 ± 2.2 8.6 ± 2.2 8.3 ± 1.7 7.9 ± 1.4 8.0 ± 1.4 7.6 ± 1.4
FPG, n (%) 119 – 164 – 74 – 14 – 153 – 381 – 244 – 57 –
Mean ± SD, mg/dl 244.6 ± 103.7 221.0 ± 81.8 235.3 ± 114.9 236.1 ± 79.3 167.6 ± 78.2 147.7 ± 60.5 155.1 ± 69.5 158.4 ± 84.0
eGFR, n (%) 287 – 382 – 193 – 43 – 428 – 1075 – 747 – 187 –
Mean ± SD, mL/min/1.73 m2 110.8 ± 18.5 74.2 ± 8.0 47.5 ± 8.3 18.0 ± 7.5 107.2 ± 19.5 73.9 ± 8.2 48.3 ± 8.2 17.9 ± 8.7
GLP-1 receptor agonist†† 23 (14.5) 41 (15.6) 23 (14.0) 5 (14.7) 54 (12.6) 123 (11.4) 78 (10.4) 18 (9.6)
Insulin††, n (%)
Long-acting 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 383 (89.5) 1001 (93.1) 670 (89.7) 168 (89.8)
Intermediate 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (1.2) 6 (0.6) 5 (0.7) 2 (1.1)
Premix 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 16 (3.7) 44 (4.1) 37 (5.0) 7 (3.7)
Regular 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.7) 6 (0.6) 11 (1.5) 2 (1.1)
Rapid 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 181 (42.3) 446 (41.5) 362 (48.5) 96 (51.3)
Oral antidiabetic drugs††, n (%)
Sulfonylurea 61 (38.4) 106 (40.5) 70 (42.7) 6 (17.6) 60 (14.0) 177 (16.5) 79 (10.6) 11 (5.9)
Biguanide 80 (50.3) 120 (45.8) 54 (32.9) 6 (17.6) 196 (45.8) 384 (35.7) 174 (23.3) 5 (2.7)
DPP-4 inhibitor 86 (54.1) 152 (58.0) 111 (67.7) 30 (88.2) 170 (39.7) 480 (44.7) 361 (48.3) 96 (51.3)
SGLT2 inhibitor 31 (19.5) 42 (16.0) 22 (13.4) 1 (2.9) 95 (22.2) 194 (18.0) 84 (11.2) 6 (3.2)
T2D, type 2 diabetes mellitus; SD, standard deviation; BMI, body mass index; FPG, fasting plasma glucose; eGFR, estimated glomerular filtration rate; GLP, glucagon-like peptide; DPP-4, dipeptidyl
peptidase-4; SGLT2, Sodium-glucose transport protein 2
† BMI is calculated as weight in kilograms divided by the square of the height in meters















































Table 3 – The mean Gla-300 administration, HbA1c level, body weight, and FPG level at baseline and at months 6 and 12 (LOCF) and the changes between baseline and at




















Mean ± SD, U/day
Baseline 7.5 ± 4.8 7.8 ± 4.8 7.2 ± 4.6 7.1 ± 4.7 14.9 ± 9.6 17.3 ± 11.1 13.6 ± 8.0 12.2 ± 7.5
Month 6† 10.9 ± 6.4 11.8 ± 6.8 9.5 ± 5.3 10.3 ± 6.8 15.7 ± 9.9 18.1 ± 11.3 14.4 ± 8.3 12.9 ± 8.0
Month 12 (LOCF) 10.3 ± 6.8 11.4 ± 7.4 9.2 ± 5.4 9.2 ± 6.4 15.6 ± 10.0 18.0 ± 11.3 14.6 ± 8.8 12.7 ± 8.0
Change 2.8 ± 5.8 3.6 ± 6.7 2.0 ± 4.2 2.1 ± 5.1 0.7 ± 3.8 0.7 ± 4.1 0.9 ± 3.6 0.5 ± 3.4
Paired t-test††, p-value p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
HbA1c, n 1006 – 527 – 282 – 197 – 3079 – 1331 – 1050 – 698 –
Mean ± SD, %
Baseline 9.8 ± 2.2 10.4 ± 2.3 9.1 ± 1.8 9.4 ± 2.0 8.0 ± 1.5 8.3 ± 1.7 7.8 ± 1.2 7.8 ± 1.3
Month 6††† 7.7 ± 1.4 7.8 ± 1.6 7.5 ± 1.2 7.7 ± 1.4 7.8 ± 1.3 8.0 ± 1.5 7.7 ± 1.1 7.6 ± 1.0
Month 12 (LOCF) 7.8 ± 1.5 7.9 ± 1.6 7.5 ± 1.3 8.0 ± 1.5 7.8 ± 1.3 8.0 ± 1.5 7.7 ± 1.2 7.7 ± 1.2
Change 2.0 ± 2.3 2.4 ± 2.5 1.6 ± 1.9 1.4 ± 1.9 0.2 ± 1.2 0.3 ± 1.4 0.1 ± 1.0 0.1 ± 1.0
Paired t-test††, p-value p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.006 p = 0.009
Body weight, n 888 – 480 – 246 – 162 – 2706 – 1193 – 927 – 586 –
Mean ± SD, kg
Baseline 66.7 ± 15.6 72.1 ± 16.3 62.4 ± 11.9 57.3 ± 11.2 67.2 ± 15.2 73.7 ± 16.7 63.8 ± 11.8 59.3 ± 10.6
Month 6†††† 67.8 ± 15.5 73.6 ± 15.9 61.9 ± 11.6 58.9 ± 11.3 67.2 ± 15.1 73.7 ± 16.3 63.6 ± 12.0 59.2 ± 10.4
Month 12 (LOCF) 67.4 ± 15.4 73.1 ± 16.0 62.6 ± 11.8 57.8 ± 11.0 67.0 ± 15.1 73.7 ± 16.4 63.6 ± 12.0 58.9 ± 10.4
Change 0.7 ± 4.1 0.9 ± 4.6 0.2 ± 3.4 0.5 ± 3.5 0.2 ± 3.1 0.1 ± 3.4 0.2 ± 3.0 0.4 ± 2.6
Paired t-test††, p-value p < 0.001 p < 0.001 p = 0.352 p = 0.053 p = 0.003 p = 0.560 p = 0.051 p < 0.001
FPG, n 332 – 164 – 104 – 64 – 905 – 400 – 308 – 197 –
Mean ± SD, mg/dl
Baseline 229.2 ± 91.6 230.9 ± 88.0 209.0 ± 81.6 257.5 ± 108.1 156.8 ± 69.4 162.8 ± 77.4 147.1 ± 54.1 159.7 ± 71.9
Month 6††††† 149.4 ± 44.7 147.9 ± 42.1 152.9 ± 53.9 147.5 ± 34.0 143.9 ± 52.0 145.8 ± 53.2 143.0 ± 50.4 141.3 ± 52.2
Month 12 (LOCF) 147.2 ± 55.0 145.0 ± 50.5 143.2 ± 57.8 159.4 ± 60.2 147.5 ± 59.7 151.2 ± 62.3 144.5 ± 58.1 144.6 ± 56.2
Change 82.0 ± 97.0 85.9 ± 96.1 65.9 ± 90.9 98.1 ± 106.5 9.3 ± 69.5 11.6 ± 75.1 2.6 ± 65.2 15.1 ± 63.7
Paired t-test††, p-value p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.002 p = 0.486 p = 0.001
FPG, fasting plasma glucose; LOCF, last observation carried forward; T2D, type 2 diabetes mellitus; SD, standard deviation.
† n = 848, 447, 250, and 151 for insulin-naı̈ve and n = 2940, 1267, 1024, and 649 for insulin-experienced and for total, <65, 65–<75, and 75 years, respectively
†† Paired-t test was used to compare changes between baseline and at month 12 (LOCF).
††† n = 767, 413, 217, and 137 for insulin-naı̈ve and n = 2739, 1185, 953, and 601 for insulin-experienced for total, age <65, 65–<75, and 75 years, respectively
†††† n = 651, 358, 186, and 107 for insulin-naı̈ve and n = 2312, 1039, 794, and 479 for insulin-experienced and for total, <65, 65–<75, and 75 years, respectively















































Table 4 – The mean Gla-300 administration, HbA1c level, body weight, and FPG level at baseline and at months 6 and 12 (LOCF) and the changes between baseline and at
month 12 (LOCF) among insulin-naı̈ve and insulin-experienced people with T2D in the eGFR subgroups.
Insulin-naı̈ve Insulin-experienced


















Mean ± SD, U/day
Baseline 7.4 ± 4.2 6.8 ± 3.6 7.4 ± 5.6 6.0 ± 3.5 17.1 ± 11.9 14.1 ± 8.8 14.5 ± 9.6 12.3 ± 8.4
Month 6† 11.7 ± 6.6 10.1 ± 5.6 10.5 ± 7.3 9.0 ± 5.4 18.2 ± 11.9 14.9 ± 9.2 15.0 ± 9.8 13.2 ± 9.2
Month 12 (LOCF) 10.8 ± 7.1 9.7 ± 6.1 10.1 ± 7.1 7.2 ± 4.8 18.0 ± 11.9 14.8 ± 9.3 15.2 ± 10.2 12.9 ± 8.8
Change 3.5 ± 6.7 2.9 ± 5.7 2.6 ± 5.3 1.2 ± 4.1 0.9 ± 5.0 0.7 ± 3.0 0.7 ± 3.9 0.6 ± 3.6
Paired t-test††, p-value p < 0.001 p < 0.001 p < 0.001 p = 0.061 p < 0.001 p < 0.001 p < 0.001 p = 0.028
HbA1c, n 253 – 343 – 163 – 26 – 410 – 1031 – 690 – 154 –
Mean ± SD, %
Baseline 10.8 ± 2.3 9.7 ± 2.1 9.5 ± 2.2 8.0 ± 1.6 8.3 ± 1.7 7.9 ± 1.4 7.9 ± 1.4 7.6 ± 1.5
Month 6††† 7.8 ± 1.6 7.6 ± 1.3 7.7 ± 1.5 6.6 ± 1.1 8.0 ± 1.4 7.8 ± 1.2 7.7 ± 1.2 7.4 ± 1.3
Month 12 (LOCF) 7.9 ± 1.6 7.8 ± 1.5 7.8 ± 1.6 6.9 ± 1.4 8.0 ± 1.3 7.8 ± 1.3 7.8 ± 1.3 7.4 ± 1.2
Change 2.9 ± 2.6 2.0 ± 2.2 1.6 ± 2.1 1.1 ± 1.7 0.3 ± 1.4 0.2 ± 1.2 0.2 ± 1.2 0.2 ± 1.1
Paired t-test††, p-value p < 0.001 p < 0.001 p < 0.001 p = 0.003 p < 0.001 p < 0.001 p < 0.001 p = 0.021
Body weight, n 235 – 295 – 146 – 27 – 355 – 897 – 591 – 142 –
Mean ± SD, kg
Baseline 69.8 ± 18.1 65.7 ± 14.9 65.0 ± 12.8 65.7 ± 18.6 70.0 ± 19.0 66.6 ± 14.4 66.1 ± 14.0 68.6 ± 15.4
Month 6†††† 71.2 ± 18.2 67.0 ± 14.7 65.2 ± 13.1 67.5 ± 17.8 70.2 ± 18.6 66.7 ± 14.4 66.0 ± 14.1 67.7 ± 14.0
Month 12 (LOCF) 71.1 ± 18.2 66.0 ± 14.4 65.3 ± 12.8 66.7 ± 18.1 70.0 ± 18.6 66.4 ± 14.3 65.8 ± 14.1 68.5 ± 16.0
Change 1.3 ± 5.0 0.3 ± 3.7 0.2 ± 3.7 1.0 ± 4.4 0.0 ± 3.6 0.2 ± 3.0 0.3 ± 2.9 0.1 ± 3.8
Paired t-test††, p-value p < 0.001 p = 0.235 p = 0.461 p = 0.265 p = 0.830 p = 0.079 p = 0.016 p = 0.804
FPG, n 94 – 115 – 55 – 10 – 136 – 334 – 208 – 47 –
Mean ± SD, mg/dl
Baseline 239.6 ± 98.6 218.5 ± 83.3 231.8 ± 111.0 233.5 ± 69.8 168.4 ± 80.5 149.0 ± 61.4 152.1 ± 68.5 162.1 ± 90.4
Month 6††††† 154.5 ± 48.6 136.3 ± 38.2 149.3 ± 50.0 128.0 ± 26.2 144.7 ± 50.9 141.1 ± 54.3 138.2 ± 46.8 144.8 ± 60.7
Month 12 (LOCF) 149.7 ± 54.5 142.7 ± 53.4 145.6 ± 65.9 155.0 ± 65.2 147.7 ± 54.5 144.4 ± 54.8 142.4 ± 49.5 138.7 ± 49.7
Change 89.9 ± 103.9 75.8 ± 81.3 86.2 ± 121.9 78.5 ± 111.0 20.7 ± 72.4 4.6 ± 55.2 9.7 ± 65.2 23.5 ± 91.3
Paired t-test††, p-value p < 0.001 p < 0.001 p < 0.001 p = 0.052 p = 0.001 p = 0.125 p = 0.033 p = 0.084
FPG, fasting plasma glucose; LOCF, last observation carried forward; T2D, type 2 diabetes mellitus; eGFR, estimated glomerular filtration rate; SD, standard deviation
† n = 188, 267, 127, and 24 for insulin-naı̈ve and n = 374, 952, 624, and 149 for insulin-experienced and for eGFR 90, 60–<90, 30–<60, and <30 mL/min/1.73 m2, respectively
†† Paired-t test was used to compare changes between baseline and at month 12 (LOCF).
††† n = 190, 252, 125, and 17 for insulin-naı̈ve and n = 370, 923, 608, and 128 for insulin-experienced for eGFR 90, 60–<90, 30–<60, and <30 mL/min/1.73 m2, respectively
†††† n = 163, 216, 107, and 14 for insulin-naı̈ve and n = 312, 753, 496, and 107 for insulin-experienced and for eGFR 90, 60–<90, 30–<60, and <30 mL/min/1.73 m2, respectively















































Fig. 1 – (A) Percentage of insulin-naı̈ve and insulin-experienced people with T2D categorized according to HbA1c level at
month 12 (LOCF) and age, (B) proportion of people with 1 hypoglycemia at 12 months of Gla-300 administration among
insulin-naı̈ve and insulin-experienced people of the age and eGFR subgroups, (C) proportion of people with 1 hypoglycemia
during Gla-300 administration among insulin-naı̈ve and insulin-experienced people in subgroups of age and HbA1c level at
12 months (LOCF). T2D, type 2 diabetes mellitus; LOCF, last observation carried forward; eGFR, estimated glomerular filtration
rate. Notes: People with missing HbA1c values or data on hypoglycemia were excluded when calculating the proportions.
Data from the effective analysis population (A) and the safety analysis population (B, C) [22] were used for analysis.
8 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 74.7% of insulin-naı̈ve and 4.7%, 4.6%, 4.6%, and 4.8% of
insulin-experienced people in subgroups of 90, 60–<90, 30–
<60, and <30 mL/min/1.73 m2, respectively, experienced hypo-
glycemia (Fig. 1B).
The proportion of people who experienced hypoglycemia
by both age and HbA1c value at month 12 (LOCF) is shown
in Fig. 1C. In insulin-naı̈ve people, the proportions of people
who experienced hypoglycemia with HbA1c level below and
at or above 7.0% were 0.0% to 5.3% and 0.0% to 4.0%, respec-
tively, across the three age groups, whereas 1.3% to 6.7%
and 1.8% to 5.8%, respectively, in insulin-experienced people.
In all three age groups, people with lower HbA1c levels did not
show apparent increase in hypoglycemia.3.4. People who did and did not experience hypoglycemia
The baseline characteristics of people who did or did not
experience hypoglycemia during this study period are sum-
marized in Supplementary Table 3. Mean ± SD age (64.1 ± 15.
7 years vs 62.1 ± 14.0 years in insulin-naı̈ve, 64.7 ± 12.3 years
vs 64.9 ± 12.5 years in insulin-experienced), eGFR (77.0 ± 37.
8 mL/min/1.73 m2 vs 77.5 ± 29.2 mL/min/1.73 m2 in insulin-
naı̈ve, 66.8 ± 27.2 mL/min/1.73 m2 vs 67.7 ± 26.8 mL/min/1.7
3 m2 in insulin-experienced) and HbA1c at month 12 (LOCF)
(7.9 ± 1.3% vs 7.8 ± 1.5% in insulin-naı̈ve, 7.6 ± 1.1% vs
7.8 ± 1.3% in insulin-experienced) were comparable between
the two groups. The proportions of people who experienced
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 7 9hypoglycemia within 3 months before Gla-300 administration
(5.6% vs 0.9% in insulin-naı̈ve, 46.4% vs 8.7% in insulin-
experienced) and who concomitantly used rapid insulin
(33.3% vs 14.9% in insulin-naı̈ve, 68.5% vs 43.6% in insulin-
experienced) are higher and mean BMI (23.0 ± 3.9 kg/m2 vs
24.9 ± 4.7 kg/m2 in insulin-naı̈ve, 24.7 ± 4.9 kg/m2 vs 25.5 ± 4.
7 kg/m2 in insulin-experienced) was slightly lower in the
group with hypoglycemia.
4. Discussion
This study investigated the risk of hypoglycemia in people
with T2D who initiated or switched to Gla-300 in a real-
world clinical setting in Japan, using the subgroup analysis
with respect to age and eGFR.
Among the age-stratified subgroups, people aged <65 years
in insulin naı̈ve group showed the highest baseline HbA1c
(10.4%) and the greatest reduction in HbA1c (2.4%). At
month 12 month (LOCF), there were no apparent trends in
terms of HbA1c (Fig. 1A, Table 3) and the proportion of people
with hypoglycemia (Fig. 1B). Regarding the relationship
between the final HbA1c value at month 12 (LOCF) and the
proportion of hypoglycemia, people with HbA1c level <7.0%
did not show an apparent increase in hypoglycemia among
any subgroups, compared to those with HbA1c level at or
above 7.0% in both insulin-naı̈ve and insulin-experienced
people. Our results that people aged >65 years with HbA1c
below 7.0% did not show an apparent increased risk of hypo-
glycemia may provide reassuring information on the use of
Gla-300 for older people.
The Japan Diabetes Society (JDS) guideline recommends
lower limits of HbA1c target values for older people according
to their cognitive function, activities of daily living, and use of
insulin-related agents (insulin or sulfonylurea) since 2016 to
avoid (severe) hypoglycemia and minimize hypoglycemia-
related consequences [26]. A survey of severe hypoglycemia
conducted by JDS revealed that more cases of severe hypo-
glycemia were found in people with T2D having lower HbA1c
levels (mean of 6.8%) and those with older age (mean of
77.0 years) [27]. It should be noted that older people may be
unaware of their hypoglycemia status due to loss of forewarn-
ing symptoms [9]. As only 8 T2D individuals presented with
severe hypoglycemia (1 [0.08%] insulin-naı̈ve and 7 [0.21%]
insulin-experienced) in the X-STAR study [22], there was diffi-
culty in clarifying the association between age-HbA1c level
and severe hypoglycemia. Further studies are required to
evaluate the optimal range of HbA1c target values for older
people with T2D using Gla-300.
Among eGFR subgroups, people with eGFR > 90 in insulin-
naive group showed the highest baseline HbA1c (10.8%) and
the greatest reduction in HbA1c (2.9%), which is likely asso-
ciated with younger age (53.3 years). At month 12, HbA1c
levels at month 12 with eGFR < 60 were equal to or less than
those with normal renal function in both groups. The propor-
tion of people with hypoglycemia was generally similar in any
of the eGFR subgroups, only with slight variation. Although
hypoglycemia slightly increased from 2.4% to 4.7% as renalfunction declined in insulin-naı̈ve people, there were only
few people with eGFR < 60 mL/min/1.73 m2 (eight and two
individuals) (Fig. 1B). There was virtually no difference in
insulin-experienced people among the eGFR subgroups, with
4.7% and 4.8% of people with hypoglycemia in the eGFR sub-
groups of 90 and <30 mL/min/1.73 m2, respectively. In
BRIGHT and EDITION trials, RCTs of Gla-300, hypoglycemia
was observed more frequently in people with renal impair-
ment [18,28]. It should be noted that these studies set the tar-
get FPG level for titration of basal insulin. Although we cannot
yet reach conclusion, the findings from our subgroup analysis
suggest that renal impairment may not increase the risk of
hypoglycemia in people with T2D using Gla-300 in the real-
world clinical practice in Japan.
The mean BMI of was 24.8 and 25.5 kg/m2 in insulin-naı̈ve
and insulin-experienced peoples, respectively. This result was
similar to another real-world data of population with T2D ini-
tiating basal insulin in Japan [29] and obviously lower than
those who need insulin therapy in western countries (e.g.,
32 kg/m2, [30]). Along with lower BMI, decreased insulin secre-
tion in the early stage of T2D is a well-recognized feature in
Japanese population [31,32]. Thus, DPP-4 inhibitors are prefer-
ably prescribed from an early stage of diabetes [32–34]. In this
study, we found that the proportion of people prescribed with
DPP-4 inhibitors was particularly high in older (>65 years) and
reduced renal function subgroups (eGFR < 30 mL/min/1.73 m2)
in contrast to SGLT2 inhibitors, sulfonylurea, and biguanides
(Tables 1 and 2), which tend to be avoided in these subgroups.
These results are probably explained by little safety concern
of DPP-4 inhibitors in these subgroups [35,36]. Such prescrip-
tion patterns of DPP-4 inhibitors in high-risk people may
reflect that Japanese physicians have a strong sense of trust
in this class of drugs.
This study has several limitations. Firstly, relatively small
numbers of people with hypoglycemia found in this study
could be due to hypoglycemia not strictly defined and mea-
sured in the X-STAR study unlike in clinical trials. A total of
36 (2.93%) insulin-naı̈ve and 131 (3.86%) insulin-experienced
people experienced hypoglycemia during the X-STAR study,
and severe hypoglycemia were found in 1 (0.08%) and 7
(0.21%) in insulin-naı̈ve and insulin experienced people) in
the X-STAR study [22], but there might have been asymp-
tomatic people not included in these numbers. Thus, hypo-
glycemia may have been underreported, and the results
should be interpreted with care. However, our results provide
important insights into the current situation of people with
T2D in Japan where the population is rapidly aging, and the
number of aged and people with diabetes is expected to rise
[37]. Secondly, this observational study lacks a control group
and prevents any comparative analysis against other types
of insulins. This study also revealed the background charac-
teristics and the preference of concomitant OADs when initi-
ating and switching insulin therapy in clinical settings, and
such information may inform clinical practice for glycemic
control. Finally, because this is a post-marketing surveillance
conducted in Japan, our study results may not be
generalizable.
10 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 75. Conclusion
In this subgroup analysis among people with T2D who initi-
ated or switched to Gla-300 extracted from the real-world X-
STAR study in Japan, we found that the number of people
who experienced hypoglycemia was generally similar across
the age and eGFR subgroups, and people below the HbA1c
level target of 7.0% did not show an apparent increase in
hypoglycemic events in all age groups including people aged
75 years. Given that people with T2D who are older and/or
with CKD are expected to rise in aging societies such as those
in Japan, our result would provide reassuring information on
Gla-300.
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